Abivax (ABVX) Return on Capital Employed (2025 - 2026)
Abivax (ABVX) recorded quarterly Return on Capital Employed of 50.43% in Q1 2026, down 16.64% quarter-over-quarter from 43.23% in Q4 2025, and up 16829.0% on a YoY basis from N/an in Q1 2025.
Abivax (ABVX) Return on Capital Employed (2025 - 2026) Analysis & Trends
Abivax's Return on Capital Employed history runs 2 years deep, the most recent figure standing at 50.43% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 16829.0% year-over-year to 50.43%; the TTM figure through Mar 2026 stood at 50.43% (up 16829.0% YoY), while the FY2025 annual figure was 76.11%, up 2374.0% from the prior year.
- Return on Capital Employed was 50.43% for Q1 2026 at Abivax, down from 43.23% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 43.23% in Q4 2025 to a low of 716.91% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 10.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.43% |
| Dec 31, 2025 | -43.23% |
| Sep 30, 2025 | -67.94% |
| Jun 30, 2025 | -716.91% |
| Mar 31, 2025 | -218.72% |